F Prime, Inc. is a venture capital firm based in Cambridge, Massachusetts, with additional offices in San Francisco and London. Founded in 1969, it is part of the legacy of Fidelity Investments, one of the largest asset management firms in the world. F Prime focuses on investing in North American and European companies across various sectors, including healthcare, life sciences, medtech, technology, and health information technology. The firm operates several specialized funds, such as those dedicated to healthcare and life sciences, which aim to support early-stage companies in these industries. With a commitment to fostering entrepreneurship, F Prime leverages its extensive insights, domain expertise, and relationships to assist entrepreneurs in building impactful companies, all while avoiding the pressures of external fundraising.
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, that specializes in health data aggregation and centralization. Founded in 2017, the company offers a platform that secures data transmission between health systems and consumer applications. This platform consolidates health data from various electronic medical record systems into a digital health record controlled by the user, facilitating seamless sharing with healthcare providers. It also enables providers to access and query the most current patient data across multiple connected health systems. Additionally, 1upHealth's platform supports developers in obtaining clinical data from various clinics and hospitals, promoting better healthcare outcomes and cost reduction through enhanced data accessibility.
Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Zus Health helps a new wave of healthcare builders to create technologies and services without the usual blockers. Zus Health aims to bring forth a better health reality by empowering an inspired new wave of healthcare builders to create digital technologies and services that are cheaper, easier to customize, and far more intimate.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, that specializes in health data aggregation and centralization. Founded in 2017, the company offers a platform that secures data transmission between health systems and consumer applications. This platform consolidates health data from various electronic medical record systems into a digital health record controlled by the user, facilitating seamless sharing with healthcare providers. It also enables providers to access and query the most current patient data across multiple connected health systems. Additionally, 1upHealth's platform supports developers in obtaining clinical data from various clinics and hospitals, promoting better healthcare outcomes and cost reduction through enhanced data accessibility.
Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.
Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
Atalanta Therapeutics is a biotechnology company focused on developing innovative treatment options for neurodegenerative diseases through its proprietary RNA interference platform. The company aims to create therapeutics that target various conditions, including Huntington's disease by specifically targeting the HTT gene. By addressing the underlying causes of these diseases, Atalanta Therapeutics seeks to provide clinicians with effective strategies to halt disease progression and improve patient outcomes.
Citrine Medicine
Series A in 2020
Citrine Medicine is a rare disease-focused pharmaceutical firm.
WellAir delivers energy-efficient technologies that enable safe indoor spaces for the health and wellbeing of all individuals.
WellAir’s mission is to mitigate microorganisms that lead to infectious diseases, including viruses, by delivering innovative and powerful air cleaning technology and surface disinfection devices.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
NFlection Therapeutics, Inc., a biotechnology company, focuses on the discovery and development of targeted therapies for rare disorders. It offers therapies, such as RASopathies that are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. The company also develops soft mitogen-activated protein kinase (MEK) to mitigate and treat cutaneous neurofibromas in neurofibromatosis type 1. NFlection Therapeutics, Inc. was incorporated in 2014 and is based in Wayne, Pennsylvania.
PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.
Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Wellframe is a hospital and healthcare it provides a digital health management solutions that include care management support, digital concierge solutions, and transformation services. It helps healthcare organizations by providing solutions that enable them to support people longitudinally between traditional clinical interactions.
The company was founded in 2011 and headquartered in Boston, Massachusetts, United States.
Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.
Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
TraceLink, Inc. provides a comprehensive track and trace network solution designed to connect the life sciences supply chain and combat counterfeit prescription drugs. The company specializes in pharmaceutical serialization and compliance services, offering the TraceLink Life Sciences Cloud, which facilitates global connectivity and visibility throughout the pharmaceutical supply chain. Key products include the Smart Rx Manager, which helps healthcare providers comply with European Union regulations, and EU FMD Express, tailored for smaller pharmaceutical firms. Additionally, the Serialized Product Intelligence application enables users to monitor supply chain operations and address potential issues. TraceLink serves a wide range of clients, including pharmaceutical companies and wholesale distributors, and has established strategic partnerships with industry leaders. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink has expanded its presence with offices in the United Kingdom, India, Singapore, and Brazil, and is recognized for its contributions to improving supply chain performance and reducing risks in global pharmaceutical distribution.
Flywire operates an online payment platform that facilitates both domestic and international transactions, catering primarily to the education and healthcare sectors. The platform enables users, including international students and patients seeking medical care abroad, to make payments in various currencies through familiar online and offline options. By leveraging vertical-specific insights and technology, Flywire streamlines the payment process and enhances operational efficiency while minimizing risks associated with invoicing and payment reconciliation. The company, which was founded in 2009 and is headquartered in Boston, Massachusetts, has established partnerships with TRUE North and Adyen to bolster its offerings. With a significant portion of its revenue generated from the Americas, Flywire continues to expand its services to meet the needs of its diverse clientele.
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.
TraceLink, Inc. provides a comprehensive track and trace network solution designed to connect the life sciences supply chain and combat counterfeit prescription drugs. The company specializes in pharmaceutical serialization and compliance services, offering the TraceLink Life Sciences Cloud, which facilitates global connectivity and visibility throughout the pharmaceutical supply chain. Key products include the Smart Rx Manager, which helps healthcare providers comply with European Union regulations, and EU FMD Express, tailored for smaller pharmaceutical firms. Additionally, the Serialized Product Intelligence application enables users to monitor supply chain operations and address potential issues. TraceLink serves a wide range of clients, including pharmaceutical companies and wholesale distributors, and has established strategic partnerships with industry leaders. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink has expanded its presence with offices in the United Kingdom, India, Singapore, and Brazil, and is recognized for its contributions to improving supply chain performance and reducing risks in global pharmaceutical distribution.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
Kyruus, Inc. develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, the company offers a range of analytically driven tools designed to enhance the engagement and management of large physician networks. Key products include Kyruus Passport, which tracks physician productivity and performance, and Kyruus Profiles, which provides administrators with insights into physician activity. Additionally, Kyruus MDSeekyr helps users identify high-value providers, while Kyruus Insight Reports enables executives to analyze physician network performance over time. The company's ProviderMatch suite further enhances patient-provider matching and streamlines the scheduling process, ensuring a consistent patient experience across various access points. By leveraging big data, Kyruus aims to align provider supply with patient demand effectively.
Valor Performance is digital learning platform focused on igniting and sustaining peak performance for managers and executives.
Valor closes the professional training gap through a dynamic digital platform, progress metrics, and personalized programs for all Valor recipients – giving them a premium experience while fostering a performance mindset.
Founded in 2017, Valor Performance is headquartered in Boston, Massachusetts.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, aiming to provide alternatives to insulin injections. The company emerged from research by Professor Douglas Melton, which led to the discovery of a method for generating billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics, which is now dedicated to creating a cell-based therapy that combines these proprietary cells with advanced devices to effectively replace the missing beta cells in diabetic patients without the need for immunosuppression. Established in 2014 and headquartered in Cambridge, Massachusetts, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is committed to bringing its novel therapeutic solutions to clinical settings, ultimately enhancing the quality of life for individuals living with diabetes.
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.
Valor Performance is digital learning platform focused on igniting and sustaining peak performance for managers and executives.
Valor closes the professional training gap through a dynamic digital platform, progress metrics, and personalized programs for all Valor recipients – giving them a premium experience while fostering a performance mindset.
Founded in 2017, Valor Performance is headquartered in Boston, Massachusetts.
Threat Stack specializes in providing security solutions tailored for cloud infrastructure, enabling DevOps and SecOps teams to innovate and scale securely. The Threat Stack Cloud Security Platform and Cloud SecOps Program are designed to address complex cloud security needs by delivering continuous security monitoring and risk assessment. This approach helps organizations identify and verify insider threats, external attacks, and compliance gaps in real-time. By focusing on cloud, hybrid-cloud, and containerized environments, Threat Stack empowers security and operations teams to effectively manage risk and compliance across their entire infrastructure.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Wellframe is a hospital and healthcare it provides a digital health management solutions that include care management support, digital concierge solutions, and transformation services. It helps healthcare organizations by providing solutions that enable them to support people longitudinally between traditional clinical interactions.
The company was founded in 2011 and headquartered in Boston, Massachusetts, United States.
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, aiming to provide alternatives to insulin injections. The company emerged from research by Professor Douglas Melton, which led to the discovery of a method for generating billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics, which is now dedicated to creating a cell-based therapy that combines these proprietary cells with advanced devices to effectively replace the missing beta cells in diabetic patients without the need for immunosuppression. Established in 2014 and headquartered in Cambridge, Massachusetts, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is committed to bringing its novel therapeutic solutions to clinical settings, ultimately enhancing the quality of life for individuals living with diabetes.
Ivenix is a medical technology company that develops a next-generation infusion management system. It is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow.
The company was founded in 2007 and is headquartered in Amesbury, Massachusetts.
TraceLink, Inc. provides a comprehensive track and trace network solution designed to connect the life sciences supply chain and combat counterfeit prescription drugs. The company specializes in pharmaceutical serialization and compliance services, offering the TraceLink Life Sciences Cloud, which facilitates global connectivity and visibility throughout the pharmaceutical supply chain. Key products include the Smart Rx Manager, which helps healthcare providers comply with European Union regulations, and EU FMD Express, tailored for smaller pharmaceutical firms. Additionally, the Serialized Product Intelligence application enables users to monitor supply chain operations and address potential issues. TraceLink serves a wide range of clients, including pharmaceutical companies and wholesale distributors, and has established strategic partnerships with industry leaders. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink has expanded its presence with offices in the United Kingdom, India, Singapore, and Brazil, and is recognized for its contributions to improving supply chain performance and reducing risks in global pharmaceutical distribution.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
Codeship Inc. is a provider of hosted continuous integration solutions that specialize in automating the build, testing, and deployment of Docker-based applications. Founded in 2011 and based in Boston, Massachusetts, with an additional office in Vienna, Austria, the company aims to streamline development cycles for software companies, thereby reducing the risk of bugs and fostering innovation. By managing the testing and release processes, Codeship allows developers to focus on creating better products more quickly. In January 2013, the company changed its name from Railsonfire Limited and, as of February 2018, operates as a subsidiary of CloudBees, Inc.
Toast, Inc. is a Boston-based technology company that specializes in developing an all-in-one point-of-sale and restaurant management software tailored for the foodservice and hospitality industries. Founded in 2011, Toast's cloud-based platform provides a comprehensive suite of features, including tableside ordering, online ordering, labor management, and real-time reporting, designed to enhance operational efficiency for restaurants, cafes, bars, and other food establishments. The software facilitates quick menu updates and integrates front-of-house and back-of-house operations, enabling restaurants to streamline their processes and improve guest experiences. With additional offices in Portland, Omaha, and Dublin, Toast aims to support restaurateurs in delivering exceptional service and achieving business success.
Codeship Inc. is a provider of hosted continuous integration solutions that specialize in automating the build, testing, and deployment of Docker-based applications. Founded in 2011 and based in Boston, Massachusetts, with an additional office in Vienna, Austria, the company aims to streamline development cycles for software companies, thereby reducing the risk of bugs and fostering innovation. By managing the testing and release processes, Codeship allows developers to focus on creating better products more quickly. In January 2013, the company changed its name from Railsonfire Limited and, as of February 2018, operates as a subsidiary of CloudBees, Inc.
PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.
Kyruus, Inc. develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, the company offers a range of analytically driven tools designed to enhance the engagement and management of large physician networks. Key products include Kyruus Passport, which tracks physician productivity and performance, and Kyruus Profiles, which provides administrators with insights into physician activity. Additionally, Kyruus MDSeekyr helps users identify high-value providers, while Kyruus Insight Reports enables executives to analyze physician network performance over time. The company's ProviderMatch suite further enhances patient-provider matching and streamlines the scheduling process, ensuring a consistent patient experience across various access points. By leveraging big data, Kyruus aims to align provider supply with patient demand effectively.
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Ivenix is a medical technology company that develops a next-generation infusion management system. It is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow.
The company was founded in 2007 and is headquartered in Amesbury, Massachusetts.
Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases.
The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics.
In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, aiming to provide alternatives to insulin injections. The company emerged from research by Professor Douglas Melton, which led to the discovery of a method for generating billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics, which is now dedicated to creating a cell-based therapy that combines these proprietary cells with advanced devices to effectively replace the missing beta cells in diabetic patients without the need for immunosuppression. Established in 2014 and headquartered in Cambridge, Massachusetts, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is committed to bringing its novel therapeutic solutions to clinical settings, ultimately enhancing the quality of life for individuals living with diabetes.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
TraceLink, Inc. provides a comprehensive track and trace network solution designed to connect the life sciences supply chain and combat counterfeit prescription drugs. The company specializes in pharmaceutical serialization and compliance services, offering the TraceLink Life Sciences Cloud, which facilitates global connectivity and visibility throughout the pharmaceutical supply chain. Key products include the Smart Rx Manager, which helps healthcare providers comply with European Union regulations, and EU FMD Express, tailored for smaller pharmaceutical firms. Additionally, the Serialized Product Intelligence application enables users to monitor supply chain operations and address potential issues. TraceLink serves a wide range of clients, including pharmaceutical companies and wholesale distributors, and has established strategic partnerships with industry leaders. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink has expanded its presence with offices in the United Kingdom, India, Singapore, and Brazil, and is recognized for its contributions to improving supply chain performance and reducing risks in global pharmaceutical distribution.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Flywire operates an online payment platform that facilitates both domestic and international transactions, catering primarily to the education and healthcare sectors. The platform enables users, including international students and patients seeking medical care abroad, to make payments in various currencies through familiar online and offline options. By leveraging vertical-specific insights and technology, Flywire streamlines the payment process and enhances operational efficiency while minimizing risks associated with invoicing and payment reconciliation. The company, which was founded in 2009 and is headquartered in Boston, Massachusetts, has established partnerships with TRUE North and Adyen to bolster its offerings. With a significant portion of its revenue generated from the Americas, Flywire continues to expand its services to meet the needs of its diverse clientele.
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion. Surface is based in Cambridge, Mass.
Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Kensho Technologies, Inc. provides analytics, artificial intelligence, machine learning, and data visualization systems to global banks and investment institutions. It develops Kensho Financial Analytics Software that deploys scalable analytics systems across the commercial institutions. It also offers artificial intelligence (AI) software called Kensho Applied Mind. The company also operates a national security division called Koto. The company was incorporated in 2012 and is based in Cambridge, Massachusetts. It has additional offices in New York, New York; McLean, Virginia; and Pacific Palisades, California. As of April 8, 2018, Kensho Technologies, Inc. operates as a subsidiary of S&P Global Inc.
ownCloud is the company behind the ownCloud project – the most downloaded open source project for data and file sync, share and view. ownCloud enables businesses to host their own, on premises or remote, cloud storage while maintaining regulatory and compliance needs. Located in Boston, Massachusetts with an international office in Germany we offer your cloud with your data – your way!
Blueprint Medicines Corporation focuses on developing small molecule kinase inhibitors aimed at treating genomic drivers in cancers, rare diseases, and enhancing cancer immunotherapy. The company is advancing several key drug candidates, including avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis and other mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, currently in Phase I clinical trials. Additionally, pralsetinib targets RET-altered non-small cell lung cancer and other solid tumors, while BLU-782 is being investigated for fibrodysplasia ossificans progressive. Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the development of personalized cancer therapies by leveraging insights into cancer genomics and utilizing a proprietary chemical library to identify new therapeutic compounds. The company collaborates with various partners, including Clementia Pharmaceuticals and Genentech, to enhance its research and development efforts.
WellAir delivers energy-efficient technologies that enable safe indoor spaces for the health and wellbeing of all individuals.
WellAir’s mission is to mitigate microorganisms that lead to infectious diseases, including viruses, by delivering innovative and powerful air cleaning technology and surface disinfection devices.
Flywire operates an online payment platform that facilitates both domestic and international transactions, catering primarily to the education and healthcare sectors. The platform enables users, including international students and patients seeking medical care abroad, to make payments in various currencies through familiar online and offline options. By leveraging vertical-specific insights and technology, Flywire streamlines the payment process and enhances operational efficiency while minimizing risks associated with invoicing and payment reconciliation. The company, which was founded in 2009 and is headquartered in Boston, Massachusetts, has established partnerships with TRUE North and Adyen to bolster its offerings. With a significant portion of its revenue generated from the Americas, Flywire continues to expand its services to meet the needs of its diverse clientele.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, aiming to provide alternatives to insulin injections. The company emerged from research by Professor Douglas Melton, which led to the discovery of a method for generating billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics, which is now dedicated to creating a cell-based therapy that combines these proprietary cells with advanced devices to effectively replace the missing beta cells in diabetic patients without the need for immunosuppression. Established in 2014 and headquartered in Cambridge, Massachusetts, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is committed to bringing its novel therapeutic solutions to clinical settings, ultimately enhancing the quality of life for individuals living with diabetes.
Kensho Technologies, Inc. provides analytics, artificial intelligence, machine learning, and data visualization systems to global banks and investment institutions. It develops Kensho Financial Analytics Software that deploys scalable analytics systems across the commercial institutions. It also offers artificial intelligence (AI) software called Kensho Applied Mind. The company also operates a national security division called Koto. The company was incorporated in 2012 and is based in Cambridge, Massachusetts. It has additional offices in New York, New York; McLean, Virginia; and Pacific Palisades, California. As of April 8, 2018, Kensho Technologies, Inc. operates as a subsidiary of S&P Global Inc.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
Kyruus, Inc. develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010 and headquartered in Boston, Massachusetts, the company offers a range of analytically driven tools designed to enhance the engagement and management of large physician networks. Key products include Kyruus Passport, which tracks physician productivity and performance, and Kyruus Profiles, which provides administrators with insights into physician activity. Additionally, Kyruus MDSeekyr helps users identify high-value providers, while Kyruus Insight Reports enables executives to analyze physician network performance over time. The company's ProviderMatch suite further enhances patient-provider matching and streamlines the scheduling process, ensuring a consistent patient experience across various access points. By leveraging big data, Kyruus aims to align provider supply with patient demand effectively.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.
Blueprint Medicines Corporation focuses on developing small molecule kinase inhibitors aimed at treating genomic drivers in cancers, rare diseases, and enhancing cancer immunotherapy. The company is advancing several key drug candidates, including avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis and other mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, currently in Phase I clinical trials. Additionally, pralsetinib targets RET-altered non-small cell lung cancer and other solid tumors, while BLU-782 is being investigated for fibrodysplasia ossificans progressive. Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the development of personalized cancer therapies by leveraging insights into cancer genomics and utilizing a proprietary chemical library to identify new therapeutic compounds. The company collaborates with various partners, including Clementia Pharmaceuticals and Genentech, to enhance its research and development efforts.
Iora Health, Inc. operates a primary care healthcare system in the United States, focusing on providing comprehensive care to patients, particularly college employees and their adult dependents. Founded in 2010 and headquartered in Boston, Massachusetts, the organization emphasizes personalized care by assigning each patient a dedicated physician and a health coach. This team facilitates continuous support through various communication methods, including email, text, and video, alongside in-person visits. Iora Health also offers educational programs, such as group visits, aimed at empowering patients to manage their health effectively and achieve their health goals. The company is dedicated to removing barriers in the healthcare system, ensuring that patients receive the attention and resources they need to navigate their health journeys successfully.
FoldRx Pharmaceuticals, Inc. engages in the discovery and development of disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The companyТs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson's disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts.
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Bikam Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. Bikam's primary innovation lies in its small molecule, non-retinoid pharmacological chaperones, which target misfolded proteins within the retina. These pharmacological chaperones are designed to bind to misfolded rod opsin, a protein associated with retinitis pigmentosa, facilitating its proper trafficking to rod cell surfaces and outer segments. Through its research and development efforts, Bikam Pharmaceuticals aims to address critical unmet medical needs in the field of ophthalmology, particularly for rare genetic disorders that can lead to blindness.
Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.
FoldRx Pharmaceuticals, Inc. engages in the discovery and development of disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The companyТs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson's disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts.